CJ BIOSCIENCE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,800 KRW | -3.77% |
|
-10.39% | -14.50% |
| Sales 2022 | 4.07B 2.96M | Sales 2023 | 5.58B 4.05M | Capitalization | 147B 107M |
|---|---|---|---|---|---|
| Net income 2022 | -34.91B -25.38M | Net income 2023 | -22.91B -16.66M | EV / Sales 2022 | 36.8 x |
| Net cash position 2022 | 20.36B 14.8M | Net cash position 2023 | 55.56B 40.39M | EV / Sales 2023 | 16.4 x |
| P/E ratio 2022 |
-4.88
x | P/E ratio 2023 |
-4.99
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 49.48% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.77% | ||
| 1 week | -10.39% | ||
| Current month | -13.53% | ||
| 1 month | -5.80% | ||
| 3 months | -8.00% | ||
| 6 months | -7.38% | ||
| Current year | -14.50% |
1 week
13 750.00
15 300.00
1 month
13 750.0017 240.00
Current year
13 750.0017 500.00
1 year
12 410.0042 000.00
3 years
12 410.0073 000.00
5 years
12 410.0073 000.00
10 years
12 410.0073 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jong-Sik Chun
CEO | Chief Executive Officer | 57 | 09-10-31 |
Joon-Woo Lee
DFI | Director of Finance/CFO | - | - |
Hyeon Kim
CTO | Chief Tech/Sci/R&D Officer | 53 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yong-Soo Jung
BRD | Director/Board Member | 54 | - |
Joon-Woo Lee
DFI | Director of Finance/CFO | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 13,800 | -3.77% | 27,843 |
| 24-04-16 | 14,340 | -2.98% | 14,227 |
| 24-04-15 | 14,780 | -2.64% | 17,154 |
| 24-04-12 | 15,180 | +1.54% | 5,499 |
| 24-04-11 | 14,950 | -2.92% | 8,635 |
End-of-day quote Korea S.E., April 16, 2024
More quotes
CJ Bioscience Inc, formerly ChunLab Inc, is a Korea-based company principally engaged in the provision of microbial bioinformatics platform and solutions. The Company mainly provides microbial bioinformatics analysis services and microbiome-based healthcare services through bioinformatics database and cloud analytics platform. The Company also develops microbiome therapies and infection diagnosis solutions.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -14.50% | 90.91M | |
| -1.78% | 41.36B | |
| +43.68% | 41.3B | |
| +4.01% | 39.61B | |
| -15.14% | 25.62B | |
| +3.16% | 24.09B | |
| -24.08% | 18.38B | |
| +24.76% | 11.85B | |
| -2.67% | 11.82B | |
| +7.01% | 11.07B |
- Stock Market
- Equities
- A311690 Stock
